CASI Pharmaceuticals (CASIF) Return on Assets (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Return on Assets came in at 0.04% in Q4 2025, down 4.0% YoY from 0.05% in Q4 2024, and down 170.14% on a QoQ basis from 0.02% in Q3 2025.
CASI Pharmaceuticals (CASIF) Return on Assets (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Return on Assets data on file, last reported at 0.04% in Q4 2025.
- Quarterly Return on Assets fell 4.0% year-over-year to 0.04% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.04% (down 4.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
- Return on Assets slipped to 0.04% in Q4 2025, from 0.02% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.01% in Q4 2024 to a low of 0.04% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 0.00% |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.04% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.03% |
| Mar 31, 2025 | -0.02% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.03% |
| Jun 30, 2024 | -0.03% |
| Mar 31, 2024 | -0.01% |